Dopamine stimulates snail albumen gland glycoprotein secretion through the activation of a D1-like receptor.
The catecholamine dopamine is present in both the central nervous system and in the peripheral tissues of molluscs, where it is involved in regulating reproduction. Application of exogenous dopamine to the isolated albumen gland of the freshwater pulmonate snail Helisoma duryi (Wetherby) induces the secretion (release) of perivitelline fluid. The major protein component of the perivitelline fluid of Helisoma duryi is a native 288 kDa glycoprotein that is secreted around individual eggs and serves as an important source of nutrients for the developing embryos. The secretion of glycoprotein by the albumen gland is a highly regulated event that must be coordinated with the arrival of the fertilized ovum at the carrefour (the region where the eggs receive albumen gland secretory products). In order to elucidate the intracellular signalling pathway(s) mediating dopamine-induced glycoprotein secretion, albumen gland cAMP production and glycoprotein secretion were measured in the presence/absence of selected dopamine receptor agonists and antagonists. Dopamine D1-selective agonists dihydrexidine, 6,7-ADTN and SKF81297 stimulated cAMP production and glycoprotein secretion from isolated albumen glands whereas D1-selective antagonists SCH23390 and SKF83566 suppressed dopamine-stimulated cAMP production. Dopamine D2-selective agonists and antagonists generally had no effect on cAMP production or protein secretion. Based on the effects of these compounds, a pharmacological profile was obtained that strongly suggests the presence of a dopamine D1-like receptor in the albumen gland of Helisoma duryi. In addition, secretion of albumen gland glycoprotein was not inhibited by protein kinase A inhibitors, suggesting that dopamine-stimulated protein secretion might occur through a protein kinase A-independent pathway.
Mukai
S T
ST
Department of Biology, Faculty of Pure and Applied Sciences, York University, Toronto, Ontario, Canada M3J 1P3.
Kiehn
L
L
Saleuddin
A S M
AS
D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D001552:Benzazepines / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors; D004298:Dopamine / Q000378:metabolism*; D018491:Dopamine Agonists / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004591:Electrophoresis, Polyacrylamide Gel; D005088:Exocrine Glands / Q000187:drug effects* / Q000378:metabolism*; D005618:Fresh Water; D006023:Glycoproteins / Q000378:metabolism*; D010617:Phenanthridines / Q000494:pharmacology; D017447:Receptors, Dopamine D1 / Q000378:metabolism; D012098:Reproduction / Q000502:physiology; D015398:Signal Transduction / Q000502:physiology*; D012908:Snails / Q000378:metabolism*; D013764:Tetrahydronaphthalenes / Q000494:pharmacology
D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D001552:Benzazepines; D000242:Cyclic AMP; D017868:Cyclic AMP-Dependent Protein Kinases; D004298:Dopamine; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D006023:Glycoproteins; D010617:Phenanthridines; D017447:Receptors, Dopamine D1; D013764:Tetrahydronaphthalenes; C061532:dihydrexidine; C011639:ADTN; C067113:SK&F 81297; C044846:SKF83566